SUDA Pharmaceuticals Ltd, a leader in oro-mucosal drug delivery, is pleased to announce that the European Patent Office has informed SUDA that it intends to grant our anagrelide Patent.

The European Patent Office will grant SUDA’s Application No. 15817516.6 titled “Use of Anagrelide for Treating Cancer”. The patent has an expiry date of December 2035.

The granting of this patent is a very important step in the commercialisation process for SUDA and validates our position as the only company in the world with a patent covering the use of anagrelide in the treatment or prevention of metastatic disease in the bone or lung in a patient with a high platelet count and a solid cancers including brain, oral cavity, head and neck, thyroid, gastrointestinal, pancreatic, liver, kidney, colorectal, lungs and bronchus, ovaries, endometrium, cervix, breast prostate, skin, mesothelioma, melanoma, gall bladder and multiple myeloma.

The patent covers very broad routes of administration beyond SUDA’s proprietary oro-mucosal and hydrotrope technologies, including transdermal patches and creams lotions and gels, and injectable formulations.

SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro- mucosal drug delivery, is pleased to announce that the European Patent Office has informed SUDA that it intends to grant our anagrelide Patent.

The European Patent Office will grant SUDA’s Application No. 15817516.6 titled “Use of Anagrelide for Treating Cancer”. The patent has an expiry date of December 2035.

The granting of this patent is a very important step in the commercialisation process for SUDA and validates our position as the only company in the world with a patent covering the use of anagrelide in the treatment or prevention of metastatic disease in the bone or lung in a patient with a high platelet count and a solid cancers including brain, oral cavity, head and neck, thyroid, gastrointestinal, pancreatic, liver, kidney, colorectal, lungs and bronchus, ovaries, endometrium, cervix, breast prostate, skin, mesothelioma, melanoma, gall bladder and multiple myeloma.

The patent covers very broad routes of administration beyond SUDA’s proprietary oro-mucosal and hydrotrope technologies, including transdermal patches and creams lotions and gels, and injectable formulations.

SUDA Pharmaceuticals Ltd, a leader in oro- mucosal drug delivery, is pleased to announce that the European Patent Office has informed SUDA that it intends to grant our anagrelide Patent.

The European Patent Office will grant SUDA’s Application No. 15817516.6 titled “Use of Anagrelide for Treating Cancer”. The patent has an expiry date of December 2035.

The granting of this patent is a very important step in the commercialisation process for SUDA and validates our position as the only company in the world with a patent covering the use of anagrelide in the treatment or prevention of metastatic disease in the bone or lung in a patient with a high platelet count and a solid cancers including brain, oral cavity, head and neck, thyroid, gastrointestinal, pancreatic, liver, kidney, colorectal, lungs and bronchus, ovaries, endometrium, cervix, breast prostate, skin, mesothelioma, melanoma, gall bladder and multiple myeloma.

The patent covers very broad routes of administration beyond SUDA’s proprietary oro-mucosal and hydrotrope technologies, including transdermal patches and creams lotions and gels, and injectable formulations.